NIDA Division of Therapeutics and Medical Consequences
E265653
The NIDA Division of Therapeutics and Medical Consequences is a branch of the National Institute on Drug Abuse that oversees research and development of treatments and medical interventions related to substance use and its health impacts.
All labels observed (1)
| Label | Occurrences |
|---|---|
| NIDA Division of Therapeutics and Medical Consequences canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T2423466 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: NIDA Division of Therapeutics and Medical Consequences Context triple: [NIDA Drug Supply Program, administeredBy, NIDA Division of Therapeutics and Medical Consequences]
-
A.
NIDA International Program
NIDA International Program is a global initiative of the U.S. National Institute on Drug Abuse that fosters international collaboration in drug abuse research, training, and policy.
-
B.
NIDA Notes
NIDA Notes is a publication of the National Institute on Drug Abuse that reports on research findings and developments related to drug use, addiction, and their prevention and treatment.
-
C.
NIDA Drug Supply Program
The NIDA Drug Supply Program is a U.S. government initiative that provides researchers with controlled substances and related materials to support scientific studies on drug abuse and addiction.
-
D.
National Institute on Drug Abuse
The National Institute on Drug Abuse is a U.S. federal research agency that leads scientific study on drug use, addiction, and their health impacts to inform prevention, treatment, and policy.
-
E.
Advisory Council on the Misuse of Drugs
The Advisory Council on the Misuse of Drugs is an independent expert body in the United Kingdom that advises the government on drug-related issues, including classification, harms, and policy.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: NIDA Division of Therapeutics and Medical Consequences Target entity description: The NIDA Division of Therapeutics and Medical Consequences is a branch of the National Institute on Drug Abuse that oversees research and development of treatments and medical interventions related to substance use and its health impacts.
-
A.
NIDA International Program
NIDA International Program is a global initiative of the U.S. National Institute on Drug Abuse that fosters international collaboration in drug abuse research, training, and policy.
-
B.
NIDA Notes
NIDA Notes is a publication of the National Institute on Drug Abuse that reports on research findings and developments related to drug use, addiction, and their prevention and treatment.
-
C.
NIDA Drug Supply Program
The NIDA Drug Supply Program is a U.S. government initiative that provides researchers with controlled substances and related materials to support scientific studies on drug abuse and addiction.
-
D.
National Institute on Drug Abuse
The National Institute on Drug Abuse is a U.S. federal research agency that leads scientific study on drug use, addiction, and their health impacts to inform prevention, treatment, and policy.
-
E.
Advisory Council on the Misuse of Drugs
The Advisory Council on the Misuse of Drugs is an independent expert body in the United Kingdom that advises the government on drug-related issues, including classification, harms, and policy.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
division of a federal research institute
ⓘ
research division ⓘ |
| abbreviation |
Markov processes
ⓘ
surface form:
DTMC
|
| aimsTo |
improve treatment outcomes for people with substance use disorders
ⓘ
reduce morbidity and mortality associated with drug use ⓘ translate scientific discoveries into effective treatments ⓘ |
| collaboratesWith |
academic research institutions
ⓘ
other NIH institutes and centers ⓘ pharmaceutical companies ⓘ regulatory agencies such as the U.S. Food and Drug Administration ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| field |
addiction science
ⓘ
clinical pharmacology ⓘ public health ⓘ |
| focusesOn |
HIV and other infectious disease consequences of drug use
ⓘ
addiction treatment ⓘ behavioral interventions for substance use disorders ⓘ hepatitis C related to drug use ⓘ medical consequences of drug use ⓘ overdose prevention ⓘ pharmacotherapies for substance use disorders ⓘ substance use disorders ⓘ therapeutics development for substance use disorders ⓘ |
| fundingSource | U.S. federal government appropriations via NIH ⓘ |
| jurisdiction | federal jurisdiction of the United States government ⓘ |
| language | English ⓘ |
| locatedIn | Bethesda, Maryland (through NIDA headquarters) ⓘ |
| mission | to support research and development of treatments and medical interventions related to substance use and its health impacts ⓘ |
| oversees |
clinical development of medications for addiction
ⓘ
clinical trials of therapeutics for substance use disorders ⓘ research on medical consequences of drug use ⓘ research on treatments for substance use disorders ⓘ |
| parentOrganization |
National Institute on Drug Abuse
ⓘ
National Institutes of Health ⓘ |
| partOf | National Institute on Drug Abuse ⓘ |
| regulates | no products directly but informs regulatory decisions through research ⓘ |
| sector | public sector ⓘ |
| supports |
clinical research on addiction therapeutics
ⓘ
medication development for cannabis use disorder ⓘ medication development for nicotine and tobacco use disorder ⓘ medication development for opioid use disorder ⓘ medication development for stimulant use disorder ⓘ preclinical research on addiction therapeutics ⓘ |
| typeOfResearch |
clinical research
ⓘ
implementation research related to addiction treatments ⓘ translational research ⓘ |
| website | https://nida.nih.gov/about-nida/organization/divisions/division-therapeutics-medical-consequences ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: NIDA Division of Therapeutics and Medical Consequences Description of subject: The NIDA Division of Therapeutics and Medical Consequences is a branch of the National Institute on Drug Abuse that oversees research and development of treatments and medical interventions related to substance use and its health impacts.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
NIDA Drug Supply Program
→
administeredBy
→
NIDA Division of Therapeutics and Medical Consequences
ⓘ